Positive Results For Empagliflozin In Type 1 Diabetes Trials | Latest News RSS feed

Positive Results For Empagliflozin In Type 1 Diabetes Trials - Latest News


Provention Bio May Offer New Hope For People With Type 1 Diabetes With Latest Clinical Data

Provention Bio (PRVB) announced positive results in a study known as "At Risk" to delay patients from gaining Type 1 diabetes (T1D ... a bit of ways to go to for trial completion. ... read more

Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type

“I am very excited to contribute to the development of a new and innovative potential treatment option for Japanese patients with type 2 diabetes ... pivotal trials in the TIMES program and follow the ... read more

vTv Therapeutics Reports Positive Midstage Trial Results For Type 1 Diabetes Drug

The micro-cap biotech announced top-line results from part 1 of a Phase 2 trial, Simplici-T1, which evaluated its TTP399 in adults with Type 1 diabetes. The pipeline asset achieved a statistically ... read more

Looking for another news?


vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in ... read more


Ertugliflozin, oral semaglutide produce positive results in type 2 diabetes

SAN FRANCISCO — The SGLT2 inhibitor ertugliflozin and an oral version of the GLP-1 receptor agonist semaglutide demonstrated favorable results in patients with type 2 diabetes ... the ... read more

Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions

Zafgen previously announced positive results from its Phase 2 clinical trial conducted outside the U.S., including data for the second cohort that included doses up to 1.8 mg ... the risk is ... read more

Positive Results for Empagliflozin in Type 1 Diabetes Trials

Results from the Phase 3 EASE program showed that treatment with empagliflozin, as an adjunct to insulin in patients with type 1 diabetes, led to improved glycemic control without increasing ... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim announced positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today ... read more

Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

placebo at 1 year was observed at the group level (using the standard mixed meal tolerance test). As with many Phase 2a trials ... rates of type 1 diabetes, it is not surprising that the cohort ... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials ... adults with type 1 diabetes on ... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

INGELHEIM, Germany and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... in adults with type 1 diabetes on ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us